Structure of Entinostat
CAS No.: 209783-80-2
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Entinostat is an oral, selective class I HDAC inhibitor with IC50 values of 243 nM, 453 nM, and 248 nM for HDAC1, HDAC2, and HDAC3, respectively.
Synonyms: MS-275; SNDX-275; MS 2275
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
HDAC Inhibitors recapitulate Human Disease-Associated Microglia Signatures in vitro
Haage, Verena Claudia ; Tuddenham, John F ; Bautista, Alex ; White, Charles C ; Garcia, Frankie ; Patel, Ronak , et al.
Abstract: Disease-associated microglia (DAM), initially described in mouse models of neurodegenerative diseases, have been classified into two related states; starting from a TREM2-independent DAM1 state to a TREM2 dependent state termed DAM2, with each state being characterized by the expression of specific marker genes1. Recently, single-cell (sc)RNA-Seq studies have reported the existence of DAMs in humans2-6; however, whether DAMs play beneficial or detrimental roles in the context of neurodegeneration is still under debate7,8. Here, we present a pharmacological approach to mimic human DAM in vitro by exposing different human microglia models to selected histone deacetylase (HDAC) inhibitors. We also provide an initial functional characterization of our model system, showing a specific increase of amyloid beta phagocytosis along with a reduction of MCP-1 secretion. Additionally, we report an increase in MITF expression, a transcription factor previously described to drive expression towards the DAM phenotype. We further identify CADM1, LIPA and SCIN as DAMmarker genes shared across various proposed DAM signatures and in our model systems. Overall, our strategy for targeted microglial polarization bears great potential to further explore human DAM function and biology.
Show More >
Keywords: Disease-associated microglia (DAM) ; in vitro model systems ; human microglia ; functional analysis
Show More >
Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors
Roth, Lukas ; Gotsbacher, Michael P. ; Codd, Rachel ;
Abstract: Immobilized metal-ion affinity chromatog. (IMAC) used to purify recombinant proteins features a resin-bound 1:1 Ni(II)-iminodiacetic acid (IDA) complex. This hemi-saturated Ni(II)-IDA system containing exchangeable sites at the metal ion is re-cast as a surrogate of a coordinatively-unsaturated metalloenzyme active site, with utility for selecting compounds with metal-binding groups from mixtures as potential metalloenzyme inhibitors. Exchanging Ni(II) for other metal ions could broaden the scope of metalloenzyme target. This work examined the performance of Cu(II)-, Fe(III)-, Ga(III)-, Ni(II)-, or Zn(II)-IMAC resins to reversibly bind exptl. or clin. metalloenzyme inhibitors of Zn(II)-ACE1, Zn(II)-HDAC, Fe(II)/(III)-5-LO or Cu(II)-tyrosinase from a curated mixture (1-17). Each IMAC system gave a distinct selection profile. The Zn(II)-IMAC system selectively bound the thiol-containing Zn(II)-ACE1 inhibitors captopril and omapatrilat, and the Fe(III)-IMAC system selectively bound the Fe(II)/(III)-5-LO inhibitor licofelone, demonstrating a remarkable IMAC-metalloenzyme metal ion match. IMAC provides a simple, water-compatible platform, which could accelerate metalloenzyme inhibitor discovery.
Show More >
CAS No. : | 209783-80-2 |
Formula : | C21H20N4O3 |
M.W : | 376.41 |
SMILES Code : | O=C(OCC1=CC=CN=C1)NCC2=CC=C(C(NC3=CC=CC=C3N)=O)C=C2 |
Synonyms : |
MS-275; SNDX-275; MS 2275
|
MDL No. : | MFCD08272435 |
InChI Key : | INVTYAOGFAGBOE-UHFFFAOYSA-N |
Pubchem ID : | 4261 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H302 |
Precautionary Statements: | P280-P305+P351+P338 |
Target |
|
In Vitro:
Concentration | Treated Time | Description | References |
SKOV3 | 5 μM | 12 h | To investigate the effect of Entinostat combined with Niraparib on HRD-EXCUTE signature, results showed that the combination significantly enhanced the HRD-EXCUTE signature. | PMC10092773 |
OVCAR5 | 5 μM | 12 h | To investigate the effect of Entinostat combined with Olaparib on HRD-EXCUTE signature, results showed that the combination significantly enhanced the HRD-EXCUTE signature. | PMC10092773 |
MDA-MB-231b | 0.5μM, 5μM | 1, 3, 6, 12, or 24 h | Significantly increased LIFR mRNA expression | PMC8403155 |
MCF7 | 0.5μM, 5μM | 1, 3, 6, 12, or 24 h | Significantly increased LIFR mRNA expression | PMC8403155 |
MCA205 cells | 10 µM | 6 h | Entinostat treatment upregulated the mRNA expression of Cxcl9, 10, 11 | PMC10155037 |
Panc1 cells | 500 nM | 24 or 72 h | To investigate the effect of Entinostat on pancreatic cancer cell differentiation, results showed that Entinostat significantly increased CD24 protein levels, indicating it promoted cell differentiation. | PMC5499659 |
BxPC3 cells | 500 nM | 24 or 72 h | To investigate the effect of Entinostat on pancreatic cancer cell differentiation, results showed that Entinostat significantly increased CD24 protein levels, indicating it promoted cell differentiation. | PMC5499659 |
L3.6 cells | 500 nM | 24 or 72 h | To investigate the effect of Entinostat on pancreatic cancer cell differentiation, results showed that Entinostat significantly increased CD24 protein levels, indicating it promoted cell differentiation. | PMC5499659 |
HMC3 microglia-like cells | 10µM | 24 h | To assess the effect of Entinostat on DAM marker gene expression, results showed significant upregulation of SPP1 and CD9 expression | PMC11482930 |
HaCaT cells | 10 μM | 48 h | To examine the effect of the HDAC inhibitor entinostat on DNA methylation, it was found that BG4 signal significantly increased in open chromatin promoter regions, and methylation levels at BG4 peaks were significantly reduced. | PMC6173298 |
Human neuroendocrine SCLC cells | 2.5 μM | 24 h | To investigate the effects of Entinostat on cell cycle and DNA damage in SCLC cells. | PMC10644001 |
KU-OC-031065 | 0.25 μM | 72 h | Entinostat combined with olaparib significantly reduced the viability of KU-OC-031065 cells, showing synergistic effects. | PMC8647995 |
KU-OC-033697 | 0.25 μM | 72 h | Entinostat combined with olaparib significantly reduced the viability of KU-OC-033697 cells, showing synergistic effects. | PMC8647995 |
OVCAR-3 | 0.25 μM | 72 h | Entinostat combined with olaparib significantly reduced the viability of OVCAR-3 cells, showing synergistic effects. | PMC8647995 |
SKOV-3 | 0.25 μM | 72 h | Entinostat combined with olaparib significantly reduced the viability of HR-proficient ovarian cancer cells, showing synergistic effects. | PMC8647995 |
HNT34 | 1 μM | 72 h | To evaluate the antiproliferative effect of Entinostat on EVI1-high AML cells, results showed that Entinostat significantly inhibited cell proliferation. | PMC11150407 |
UCSD/AML1 | 1 μM | 72 h | To evaluate the antiproliferative effect of Entinostat on EVI1-high AML cells, results showed that Entinostat significantly inhibited cell proliferation. | PMC11150407 |
MOLM1 | 1 μM | 72 h | To evaluate the antiproliferative effect of Entinostat on EVI1-high AML cells, results showed that Entinostat significantly inhibited cell proliferation. | PMC11150407 |
MEWO | 1μM | 72 h | Entinostat combined with BRAF/MEK inhibitors significantly enhanced cell death, resulting in a 29% reduction in cell number. | PMC10151004 |
SKMEL2 | 1μM | 72 h | Entinostat combined with BRAF/MEK inhibitors significantly enhanced cell death, resulting in a 29% reduction in cell number. | PMC10151004 |
Hs695T | 1μM | 72 h | Entinostat combined with BRAF/MEK inhibitors significantly enhanced cell death, resulting in a 29% reduction in cell number. | PMC10151004 |
In Vivo:
Administration | Dosage | Frequency | Description | References |
Mice | HRD ovarian cancer model | Intraperitoneal injection | 5 mg/kg | Weekly for 4 weeks | To investigate the effect of Entinostat combined with Niraparib on HRD ovarian cancer model, results showed that the combination significantly inhibited tumor growth and enhanced HRD-EXCUTE signature. | PMC10092773 |
Mice | MCF7 orthotopic inoculation model | Not specified | 10mg/kg | 5 days/week until sacrifice | Significantly reduced MCF7 primary tumor growth | PMC8403155 |
SCID mice | H841 xenograft model | Entinostat: oral gavage, cisplatin: intraperitoneal injection | 25 mg/kg | Entinostat: twice a week, cisplatin: once a week, for 30 days | Combination treatment with entinostat and cisplatin significantly decreased tumor growth in vivo. Tumor weights and intratumoral Pt content were significantly higher in the combination group, which also showed enhanced apoptosis and necrosis. | PMC10644001 |
Mice | SKOV-3-IP-Luc xenograft model | Oral gavage | 15 mg/kg | Once weekly for two weeks | Entinostat combined with olaparib significantly reduced peritoneal metastases in the SKOV-3 xenograft model and prolonged survival in the CCNE1-amplified HR-proficient PDX model. | PMC8647995 |
Mice | BRAF-mutant melanoma xenograft model | Intraperitoneal injection | 1mg/kg | Once weekly for 2 weeks | Entinostat combined with BRAF/MEK inhibitors significantly enhanced tumor regression, with an average 70% reduction in tumor volume. | PMC10151004 |
Mice | MC38 and MCA205 tumor models | Oral | 30 mg/kg | Three times per week for 28 days | Entinostat significantly suppressed the growth of MC38 and MCA205 tumors in immunocompetent mice but not in immunodeficient mice | PMC10155037 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT03280563 | Breast Neoplasms | Phase 1 Phase 2 | Recruiting | October 7, 2022 | - |
NCT02623751 | Breast Cancer | Phase 1 | Active, not recruiting | February 2019 | Japan ... More >> Chikusa-ku, Aichi, Japan Chuo-ku, Osaka, Japan Chuo-ku, Tokyo, Japan Less << |
NCT00823290 | Hepatocellular Carcinoma | Phase 1 | Unknown | December 2010 | Germany ... More >> Department of Medicine 1, University Hospital Erlangen Recruiting Erlangen, Germany, 91054 Contact: Matthias Ocker, MD +49-6421-58 ext 68931 Matthias.Ocker@staff.uni-marburg.de Contact: Susanne Gahr, MD +49-9131-85 ext 35000 susanne.gahr@uk-erlangen.de Principal Investigator: Deike Strobel, MD Less << |
NCT01928576 | Non-Small Lung Cancer, Epigene... More >>tic Therapy Less << | Phase 2 | Recruiting | August 2022 | United States, California ... More >> University of Southern California Completed Los Angeles, California, United States, 90033 United States, Maryland Julie Brahmer, MD Recruiting Baltimore, Maryland, United States, 21224 Contact: Julie Brahmer, MD 410-502-7159 brahmju@jhmi.edu Contact: Jessica Wakefield 410-502-3696 jrober31@jhmi.edu Julie Brahmer, MD Recruiting Baltimore, Maryland, United States, 21287 Contact: Julie Brahmer, MD 410-502-7159 jbrahmju@jhmi.edu Contact: Jessica Wakefield 410-502-3696 jrober31@jhmi.edu United States, Pennsylvania UPMC Cancer Center- Hillman Cancer Center Recruiting Pittsburgh, Pennsylvania, United States, 15213 Contact: James G Herman, MD 412-692-4724 hermanj3@upmc.edu Less << |
NCT03291886 | Advanced or Recurrent Breast C... More >>ancer Less << | Phase 2 | Active, not recruiting | November 2021 | Japan ... More >> Aichi Cancer Center Hospital Nagoya, Aichi, Japan Nagoya City University Hospital Nagoya, Aichi, Japan Shikoku Cancer Center Matsuyama, Ehime, Japan Kitakyushu Municipal Medical Center Kitakyushu, Fukuoka, Japan Gunma Cancer Center Ota, Gunma, Japan Hokkaido Cancer Center Sapporo, Hokkaido, Japan Hokkaido University Hospital Sapporo, Hokkaido, Japan The Hospital of Hyogo College of Medicine Nishinomiya, Hyogo, Japan Tsukuba University Hospital Tsukuba, Ibaraki, Japan Tokai University Hospital Isehara, Kanagawa, Japan Kanagawa Cancer Center Yokohama, Kanagawa, Japan Nahanishi Clinic Naha, Okinawa, Japan Kindai University Hospital Osakasayama, Osaka, Japan Osaka University Hospital Suita, Osaka, Japan Saitama Medical University International Medical Center Hidaka, Saitama, Japan Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital Bunkyo, Tokyo, Japan National Cancer Center Hospital Chuo, Tokyo, Japan The Cancer Institute Hospital of JFCR Koto, Tokyo, Japan Toranomon Hospital Minato, Tokyo, Japan Showa University Hospital Shinagawa, Tokyo, Japan Chiba Cancer Center Chiba, Japan Kyushu Cancer Center Fukuoka, Japan Sagara Hospital Kagoshima, Japan Kumamoto University Hospital Kumamoto, Japan Kyoto University Hospital Kyoto, Japan Niigata Cancer Center Hospital Niigata, Japan Okayama University Hospital Okayama, Japan Osaka National Hospital Osaka, Japan Less << |
NCT00185302 | Melanoma | Phase 2 | Completed | - | - |
NCT01935947 | Recurrent Non-Small Cell Lung ... More >>Carcinoma Stage IIIA Non-Small Cell Lung Cancer Stage IIIB Non-Small Cell Lung Cancer Stage IV Non-Small Cell Lung Cancer Less << | Phase 2 | Terminated | - | United States, California ... More >> USC / Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 USC Norris Oncology/Hematology-Newport Beach Newport Beach, California, United States, 92663 United States, Maryland Johns Hopkins Bayview Medical Center Baltimore, Maryland, United States, 21224 Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States, 21287 United States, South Carolina Medical University of South Carolina Charleston, South Carolina, United States, 29425 Less << |
NCT00020579 | Cancer | Phase 1 | Completed | - | United States, Maryland ... More >> National Naval Medical Center Bethesda, Maryland, United States, 20889-5000 Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support Bethesda, Maryland, United States, 20892-1182 NCI - Center for Cancer Research Bethesda, Maryland, United States, 20892 Less << |
NCT00462605 | Adult Acute Lymphoblastic Leuk... More >>emia in Remission Adult Acute Megakaryoblastic Leukemia (M7) Adult Acute Minimally Differentiated Myeloid Leukemia (M0) Adult Acute Monoblastic Leukemia (M5a) Adult Acute Monocytic Leukemia (M5b) Adult Acute Myeloblastic Leukemia With Maturation (M2) Adult Acute Myeloblastic Leukemia Without Maturation (M1) Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) Adult Acute Myelomonocytic Leukemia (M4) Adult Erythroleukemia (M6a) Adult Pure Erythroid Leukemia (M6b) Chronic Myelomonocytic Leukemia de Novo Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable Previously Treated Myelodysplastic Syndromes Recurrent Adult Acute Lymphoblastic Leukemia Recurrent Adult Acute Myeloid Leukemia Refractory Anemia Refractory Anemia With Excess Blasts Refractory Anemia With Ringed Sideroblasts Refractory Cytopenia With Multilineage Dysplasia Secondary Acute Myeloid Leukemia Secondary Myelodysplastic Syndromes Untreated Adult Acute Lymphoblastic Leukemia Untreated Adult Acute Myeloid Leukemia Less << | Phase 2 | Completed | - | United States, Maryland ... More >> Johns Hopkins University Baltimore, Maryland, United States, 21287-8936 Less << |
NCT01935947 | - | Terminated | - | - | |
NCT00462605 | - | Completed | - | - | |
NCT00602030 | Non-Small-Cell Lung Carcinoma ... More >> Carcinoma, Non-Small Cell Lung Less << | Phase 1 Phase 2 | Completed | - | - |
NCT00015925 | Leukemia Mult... More >>iple Myeloma and Plasma Cell Neoplasm Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Diseases Less << | Phase 1 | Completed | - | United States, Maryland ... More >> Greenebaum Cancer Center at University of Maryland Medical Center Baltimore, Maryland, United States, 21201 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland, United States, 21231 Less << |
NCT00828854 | ER+ Breast Cancer | Phase 2 | Completed | - | Ireland ... More >> St. Vincent's University Hospital Dublin, Ireland United Kingdom The University of Birmingham Birmingham, United Kingdom Velindre Hospital - Whitchurch Cardiff, United Kingdom Whiston Hospital; Clatterbridge Centre for Oncology Liverpool, United Kingdom University College London Hospitals London, United Kingdom Christie Hospital, Manchester Breast Centre Manchester, United Kingdom Less << |
NCT00101179 | Acute Myeloid Leukemia ... More >> Chronic Myelomonocytic Leukemia de Novo Myelodysplastic Syndrome Leukemia Myelodysplastic Syndrome Previously Treated Myelodysplastic Syndrome Recurrent Adult Acute Myeloid Leukemia Secondary Acute Myeloid Leukemia Secondary Myelodysplastic Syndrome Untreated Adult Acute Myeloid Leukemia Less << | Phase 1 | Active, not recruiting | - | United States, Maryland ... More >> Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States, 21287 United States, New York Mount Sinai Hospital New York, New York, United States, 10029 Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 Less << |
NCT02115282 | Breast Adenocarcinoma ... More >> Estrogen Receptor Positive HER2/Neu Negative Progesterone Receptor Positive Recurrent Breast Carcinoma Stage IIIB Breast Cancer AJCC v7 Stage IIIC Breast Cancer AJCC v7 Stage IV Breast Cancer AJCC v6 and v7 Less << | Phase 3 | Active, not recruiting | - | - |
NCT00754312 | Breast Cancer | PHASE1 | TERMINATED | 2009-02-28 | Monet Bowling, MD, Indianapoli... More >>s, Indiana, United States Less << |
NCT03215264 | Colorectal Cancer | Phase 1 Phase 2 | Recruiting | July 10, 2020 | United States, Pennsylvania ... More >> Abramson Cancer Center of the University of Pennsylvania Recruiting Philadelphia, Pennsylvania, United States, 19104 Contact: Peter O'Dwyer, MD 855-216-0098 PennCancerTrials@emergingmed.com Principal Investigator: Peter O'Dwyer, MD Less << |
NCT00098891 | Adult Grade III Lymphomatoid G... More >>ranulomatosis Anaplastic Large Cell Lymphoma Angioimmunoblastic T-cell Lymphoma Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue Intraocular Lymphoma Nodal Marginal Zone B-cell Lymphoma Primary Central Nervous System Non-Hodgkin Lymphoma Recurrent Adult Burkitt Lymphoma Recurrent Adult Diffuse Large Cell Lymphoma Recurrent Adult Diffuse Mixed Cell Lymphoma Recurrent Adult Diffuse Small Cleaved Cell Lymphoma Recurrent Adult Grade III Lymphomatoid Granulomatosis Recurrent Adult Hodgkin Lymphoma Recurrent Adult Immunoblastic Large Cell Lymphoma Recurrent Adult Lymphoblastic Lymphoma Recurrent Adult T-cell Leukemia/Lymphoma Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Grade 3 Follicular Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Marginal Zone Lymphoma Recurrent Mycosis Fungoides/Sezary Syndrome Recurrent Small Lymphocytic Lymphoma Small Intestine Lymphoma Splenic Marginal Zone Lymphoma Stage IV Adult Burkitt Lymphoma Stage IV Adult Diffuse Large Cell Lymphoma Stage IV Adult Diffuse Mixed Cell Lymphoma Stage IV Adult Diffuse Small Cleaved Cell Lymphoma Stage IV Adult Hodgkin Lymphoma Stage IV Adult Immunoblastic Large Cell Lymphoma Stage IV Adult Lymphoblastic Lymphoma Stage IV Adult T-cell Leukemia/Lymphoma Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma Stage IV Grade 1 Follicular Lymphoma Stage IV Grade 2 Follicular Lymphoma Stage IV Grade 3 Follicular Lymphoma Stage IV Mantle Cell Lymphoma Stage IV Marginal Zone Lymphoma Stage IV Mycosis Fungoides/Sezary Syndrome Stage IV Small Lymphocytic Lymphoma Unspecified Adult Solid Tumor, Protocol Specific Waldenstr?m Macroglobulinemia Less << | Phase 1 | Completed | - | United States, Maryland ... More >> Johns Hopkins University Baltimore, Maryland, United States, 21287-8936 Less << |
NCT00750698 | Non Small Cell Lung Cancer | Phase 2 | Completed | - | United States, California ... More >> City of Hope Duarte, California, United States University of California San Diego La Jolla, California, United States Sharp Memorial Hospital San Diego, California, United States United States, Florida University of Miami, Miller School of Medicine Miami, Florida, United States United States, Georgia Medical College of Georgia Augusta, Georgia, United States United States, Illinois RUSH University Medical Center Chicago, Illinois, United States United States, Maryland University of Maryland Medical Center Baltimore, Maryland, United States United States, Minnesota the Mayo Clinic Rochester, Minnesota, United States United States, New York Roswell Park Cancer Institute Buffalo, New York, United States United States, North Carolina Blumenthal Cancer Center Charlotte, North Carolina, United States United States, South Carolina University of South Carolina Charleston, South Carolina, United States South Carolina Oncology Associates Columbia, South Carolina, United States Less << |
NCT00313586 | - | Completed | - | - | |
NCT03250273 | Previously Treated Unresectabl... More >>e or Metastatic Cholangiocarcinoma and Pancreatic Cancer Cholangiocarcinoma Pancreatic Cancer Metastatic Pancreatic Cancer Less << | Phase 2 | Recruiting | November 2020 | United States, Maryland ... More >> Sidney Kimmel Comprehensive Cancer Center Recruiting Baltimore, Maryland, United States, 21231 Contact: Susan Sartorius-Mergenthaler, RN 410-614-3644 Sartosu@jhmi.edu Contact: Jane Zorzi, RN 410-614-5818 Jzorzi1@jhmi.edu Less << |
NCT01207726 | Stage IA Non-Small Cell Lung C... More >>arcinoma Stage IB Non-Small Cell Lung Carcinoma Less << | Phase 2 | Terminated | - | United States, California ... More >> USC / Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 United States, Florida Moffitt Cancer Center Tampa, Florida, United States, 33612 United States, Maryland Anne Arundel Medical Center Annapolis, Maryland, United States, 21401 Greater Baltimore Medical Center Baltimore, Maryland, United States, 21204 Johns Hopkins Bayview Medical Center Baltimore, Maryland, United States, 21224 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital Baltimore, Maryland, United States, 21231 United States, Pennsylvania University of Pittsburgh Cancer Institute Pittsburgh, Pennsylvania, United States, 15232 United States, Tennessee Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States, 37232 United States, Texas University of Texas Southwestern Medical Center Dallas, Texas, United States, 75390 Less << |
NCT02115594 | Breast Cancer | Phase 2 | Withdrawn(Internal decision) | June 2016 | United States, Tennessee ... More >> Tennessee Oncololgy Nashville, Tennessee, United States, 37203 Less << |
NCT00313586 | Acute Myeloid Leukemia Arising... More >> From Previous Myelodysplastic Syndrome Adult Acute Myeloid Leukemia in Remission Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA Alkylating Agent-Related Acute Myeloid Leukemia Chronic Myelomonocytic Leukemia de Novo Myelodysplastic Syndrome Previously Treated Myelodysplastic Syndrome Recurrent Adult Acute Myeloid Leukemia Secondary Acute Myeloid Leukemia Secondary Myelodysplastic Syndrome Untreated Adult Acute Myeloid Leukemia Less << | Phase 2 | Completed | - | - |
NCT02697630 | Metastatic Uveal Melanoma | Phase 2 | Recruiting | August 2023 | Sweden ... More >> Department of oncology, Sahlgrenska University Hospital Recruiting Gothenburg, Västra Götaland Region, Sweden, SE-413 45 Contact: Lars Ny, Doctor + 46 31 342 10 00 lars.ny@vgregion.se Less << |
NCT01038778 | Clear Cell Renal Cell Carcinom... More >>a Metastatic Renal Cell Cancer Stage III Renal Cell Cancer AJCC v7 Stage IV Renal Cell Cancer AJCC v7 Less << | Phase 1 Phase 2 | Active, not recruiting | - | United States, California ... More >> USC / Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 United States, Maryland Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States, 21287 United States, New York Roswell Park Cancer Institute Buffalo, New York, United States, 14263 United States, Ohio Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States, 43210 Less << |
NCT01159301 | Adult Acute Basophilic Leukemi... More >>a Adult Acute Eosinophilic Leukemia Adult Acute Megakaryoblastic Leukemia (M7) Adult Acute Minimally Differentiated Myeloid Leukemia (M0) Adult Acute Monoblastic Leukemia (M5a) Adult Acute Monocytic Leukemia (M5b) Adult Acute Myeloblastic Leukemia With Maturation (M2) Adult Acute Myeloblastic Leukemia Without Maturation (M1) Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Del(5q) Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) Adult Acute Myelomonocytic Leukemia (M4) Adult Erythroleukemia (M6a) Adult Pure Erythroid Leukemia (M6b) Blastic Phase Chronic Myelogenous Leukemia Recurrent Adult Acute Myeloid Leukemia Unspecified Adult Solid Tumor, Protocol Specific Less << | Phase 1 | Terminated | - | United States, New York ... More >> Roswell Park Cancer Institute Buffalo, New York, United States, 14263 Less << |
NCT01349959 | Estrogen Receptor Negative ... More >> Estrogen Receptor Positive HER2/Neu Negative Male Breast Carcinoma Progesterone Receptor Negative Recurrent Breast Carcinoma Stage IIIC Breast Cancer AJCC v7 Stage IV Breast Cancer AJCC v6 and v7 Triple-Negative Breast Carcinoma Less << | Phase 2 | Completed | - | United States, California ... More >> City of Hope Comprehensive Cancer Center Duarte, California, United States, 91010 USC / Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 University of California Davis Comprehensive Cancer Center Sacramento, California, United States, 95817 United States, Maryland Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States, 21287 United States, Minnesota Unity Hospital Fridley, Minnesota, United States, 55432 Metro Minnesota Community Oncology Research Consortium Saint Louis Park, Minnesota, United States, 55416 United States, Pennsylvania University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States, 15232 Less << |
NCT01886573 | Stage IA Non-Small Cell Lung C... More >>arcinoma Stage IB Non-Small Cell Lung Carcinoma Stage IIA Non-Small Cell Lung Carcinoma Stage IIB Non-Small Cell Lung Carcinoma Stage IIIA Non-Small Cell Lung Cancer Less << | Phase 1 | Terminated | - | United States, Kentucky ... More >> University of Kentucky/Markey Cancer Center Lexington, Kentucky, United States, 40536 United States, New Mexico University of New Mexico Albuquerque, New Mexico, United States, 87106 United States, Texas University of Texas Southwestern Medical Center Dallas, Texas, United States, 75390 Less << |
NCT01349959 | - | Completed | - | - | |
NCT01105377 | Recurrent Colon Cancer ... More >> Recurrent Rectal Cancer Stage IV Colon Cancer Stage IV Rectal Cancer Less << | Phase 2 | Completed | - | United States, Arizona ... More >> Mayo Clinic in Arizona Scottsdale, Arizona, United States, 85259 United States, California University of Southern California/Norris Cancer Center Los Angeles, California, United States, 90033 United States, Florida Mayo Clinic in Florida Jacksonville, Florida, United States, 32224-9980 United States, Maryland Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland, United States, 21287 United States, Michigan Wayne State University/Karmanos Cancer Institute Detroit, Michigan, United States, 48201 United States, Minnesota Minnesota Oncology Hematology PA-Maplewood Maplewood, Minnesota, United States, 55109 Mayo Clinic Rochester, Minnesota, United States, 55905 Metro-Minnesota CCOP Saint Louis Park, Minnesota, United States, 55416 United Hospital Saint Paul, Minnesota, United States, 55102 Lakeview Hospital Stillwater, Minnesota, United States, 55082 United States, Missouri Washington University School of Medicine Saint Louis, Missouri, United States, 63110 United States, Pennsylvania University of Pittsburgh Cancer Institute Pittsburgh, Pennsylvania, United States, 15232 University of Pittsburgh Pittsburgh, Pennsylvania, United States, 15232 United States, Wisconsin University of Wisconsin Hospital and Clinics Madison, Wisconsin, United States, 53792 Less << |
NCT01305499 | Acute Myeloid Leukemia | Phase 2 | Recruiting | February 2019 | United States, Connecticut ... More >> Yale School of Medicine Not yet recruiting New Haven, Connecticut, United States, 06520 Contact: Steven Gore, MD steven.gore@yale.edu United States, Maryland Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Active, not recruiting Baltimore, Maryland, United States, 21231 United States, Ohio Cleveland Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center Not yet recruiting Cleveland, Ohio, United States, 44106 Contact: Benjamin Tomlinson, MD Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center Recruiting Cleveland, Ohio, United States, 44195 Contact: Hetty Carraway, MD, MBA 216-445-5899 carrawh@ccf.org Less << |
NCT01132573 | Acute Leukemias of Ambiguous L... More >>ineage Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia Recurrent Adult Acute Lymphoblastic Leukemia Untreated Adult Acute Lymphoblastic Leukemia Less << | Phase 1 | Completed | - | United States, Colorado ... More >> University of Colorado Anschutz Medical Campus Aurora, Colorado, United States, 80045 University of Colorado Denver, Colorado, United States, 80217-3364 United States, Maryland University of Maryland/Greenebaum Cancer Center Baltimore, Maryland, United States, 21201 Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland, United States, 21287 Less << |
NCT01105377 | - | Completed | - | - | |
NCT00676663 | Breast Cancer ... More >> Estrogen Receptor-Positive Breast Cancer Breast Cancer, Estrogen Receptor-Positive ER+ Breast Cancer Less << | Phase 2 | Completed | - | - |
NCT03538171 | Advanced Breast Cancer | Phase 3 | Recruiting | April 2023 | China, Beijing ... More >> Cancer Hospital Chinese Academy Medical Sciences Recruiting Beijing, Beijing, China, 10021 Contact: Binghe Xu, Ph D Less << |
NCT00387465 | Recurrent Non-Small Cell Lung ... More >>Carcinoma Stage IIIA Non-Small Cell Lung Cancer Stage IIIB Non-Small Cell Lung Cancer Stage IV Non-Small Cell Lung Cancer Less << | Phase 1 Phase 2 | Completed | - | United States, California ... More >> USC Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 Sidney Kimmel Cancer Center San Diego, California, United States, 92121 United States, Maryland Johns Hopkins Bayview Medical Center Baltimore, Maryland, United States, 21224 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital Baltimore, Maryland, United States, 21231 Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland, United States, 21287 Less << |
NCT03018249 | Grade 1 Endometrial Endometrio... More >>id Adenocarcinoma Grade 2 Endometrial Endometrioid Adenocarcinoma Grade 3 Endometrial Endometrioid Adenocarcinoma Uterine Corpus Adenosarcoma Less << | Phase 2 | Active, not recruiting | December 31, 2020 | - |
NCT01383447 | Philadelphia Chromosome Positi... More >>ve Adult Precursor Acute Lymphoblastic Leukemia Recurrent Adult Acute Lymphoblastic Leukemia Less << | Phase 1 Phase 2 | Terminated(This study was halt... More >>ed prematurely by the NCI for low accrual.) Less << | - | United States, Maryland ... More >> Johns Hopkins University Baltimore, Maryland, United States, 21287-8936 Less << |
NCT02453620 | Breast Adenocarcinoma ... More >> HER2/Neu Negative Invasive Breast Carcinoma Metastatic Malignant Solid Neoplasm Stage III Breast Cancer AJCC v7 Stage IIIA Breast Cancer AJCC v7 Stage IIIB Breast Cancer AJCC v7 Stage IIIC Breast Cancer AJCC v7 Stage IV Breast Cancer AJCC v6 and v7 Unresectable Solid Neoplasm Less << | Phase 1 | Recruiting | - | United States, California ... More >> City of Hope Comprehensive Cancer Center Recruiting Duarte, California, United States, 91010 Contact: Site Public Contact 800-826-4673 becomingapatient@coh.org Principal Investigator: Vincent Chung United States, Connecticut Smilow Cancer Center/Yale-New Haven Hospital Recruiting New Haven, Connecticut, United States, 06510 Contact: Site Public Contact 203-785-5702 canceranswers@yale.edu Principal Investigator: Patricia M. LoRusso Yale University Recruiting New Haven, Connecticut, United States, 06520 Contact: Site Public Contact 203-785-5702 canceranswers@yale.edu Principal Investigator: Patricia M. LoRusso United States, Maryland Johns Hopkins University/Sidney Kimmel Cancer Center Recruiting Baltimore, Maryland, United States, 21287 Contact: Site Public Contact 410-955-8804 jhcccro@jhmi.edu Principal Investigator: Roisin M. Connolly United States, Pennsylvania University of Pittsburgh Cancer Institute (UPCI) Recruiting Pittsburgh, Pennsylvania, United States, 15232 Contact: Site Public Contact 412-647-8073 Principal Investigator: Adam M. Brufsky Less << |
NCT01434303 | HER2/Neu Positive ... More >> Invasive Breast Carcinoma Recurrent Breast Carcinoma Stage IV Breast Cancer AJCC v6 and v7 Less << | Phase 1 | Active, not recruiting | - | United States, Texas ... More >> M D Anderson Cancer Center Houston, Texas, United States, 77030 Less << |
NCT01234532 | Estrogen Receptor-negative Bre... More >>ast Cancer HER2-negative Breast Cancer Progesterone Receptor-negative Breast Cancer Stage I Breast Cancer Stage II Breast Cancer Stage IIIA Breast Cancer Triple-negative Breast Cancer Less << | Phase 2 | Terminated(low accrual) | - | United States, Maryland ... More >> University of Maryland Baltimore Baltimore, Maryland, United States, 21201 Less << |
NCT02437136 | Non-Small Cell Lung Cancer ... More >> Melanoma Mismatch Repair-Proficient Colorectal Cancer Less << | Phase 1 Phase 2 | Active, not recruiting | August 2019 | United States, Connecticut ... More >> Yale University New Haven, Connecticut, United States, 06519 United States, Georgia Emory University Atlanta, Georgia, United States, 30322 United States, Maryland University of Maryland, Marlene and Stewart Greenbaum Cancer Center Baltimore, Maryland, United States, 21201 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland, United States, 21231 United States, Massachusetts Dana Farber Cancer Institution Boston, Massachusetts, United States, 02215 United States, New York Roswell Park Cancer Institute Buffalo, New York, United States, 14263 Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 United States, North Carolina The University of North Carolina at Chapel Hill Chapel Hill, North Carolina, United States, 27599 United States, Pennsylvania St Luke's University Health Network Easton, Pennsylvania, United States, 18045 United States, Tennessee Sarah Cannon Research Institute Nashville, Tennessee, United States, 37203 Vanderbilt University Medical Center Nashville, Tennessee, United States, 37230 Less << |
NCT03024437 | Metastatic Cancer ... More >> Renal Cancer Less << | Phase 1 Phase 2 | Recruiting | January 31, 2020 | United States, Indiana ... More >> Indiana University Health Hospital Recruiting Indianapolis, Indiana, United States, 46202 Contact: Sheila Dropcho, RN 317-278-4191 marlmoor@iu.edu Principal Investigator: Roberto Pili, MD Indiana University Melvin and Bren Simon Cancer Center Recruiting Indianapolis, Indiana, United States, 46202 Contact: Sheila Dropcho, RN 317-278-4191 sdropcho@iupui.edu Principal Investigator: Roberto Pili, MD United States, Pennsylvania University of Pennsylvania Not yet recruiting Philadelphia, Pennsylvania, United States, 19104 Contact: Julia Wolinkski 215-360-0928 julia.wolinksi@uphs.upenn.edu Principal Investigator: Vivek Narayan, MD Less << |
NCT01594398 | Lung Cancer N... More >>on Small Cell Lung Cancer (NSCLC) Breast Cancer Estrogen Receptor Breast Cancer Less << | Phase 1 | Completed | - | United States, Florida ... More >> Florida Cancer Specialists Sarasota, Florida, United States, 34232 United States, Oklahoma Peggy and Charles Stephenson Cancer Center Oklahoma City, Oklahoma, United States, 73104 United States, Tennessee Sarah Cannon Research Institute Nashville, Tennessee, United States, 37203 Less << |
NCT01383447 | - | Terminated(This study was halt... More >>ed prematurely by the NCI for low accrual.) Less << | - | - | |
NCT03501381 | Renal Cell Carcinoma | Phase 2 | Recruiting | April 2023 | United States, Indiana ... More >> Indiana Univeristy Melvin and Bren Simon Cancer Center Recruiting Indianapolis, Indiana, United States, 46202 Contact: Roberto Pili, MD 317-278-7776 rpili@iu.edu Principal Investigator: Roberto Pili, MD United States, Nebraska Nebraska Methodist Hospital Recruiting Omaha, Nebraska, United States, 68114 Contact: Craig Ryan craig.ryan@nmhs.org Principal Investigator: Ralph Hauke, MD Less << |
NCT00866333 | Hodgkin's Lymphoma | PHASE2 | TERMINATED | 2013-02-08 | Tower Cancer Research Foundati... More >>on, Beverly Hills, California, United States|University of Colorado, Denver, Colorado, United States|Johns Hopkins, Baltimore, Maryland, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|MD Anderson Cancer Center, Houston, Texas, United States Less << |
NCT02909452 | Neoplasms Neo... More >>plasms, Glandular and Epithelial Neoplasms by Histologic Type Bronchial Neoplasms Lung Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms Digestive System Neoplasms Endocrine Gland Neoplasms Carcinoma, Non-Small-Cell Lung Lung Diseases Breast Diseases Renal Neoplasm Solid Tumors Less << | Phase 1 | Active, not recruiting | February 2019 | United States, Texas ... More >> The START Center for Cancer Care San Antonio, Texas, United States, 78229 Less << |
NCT02780804 | Childhood Brain Stem Neoplasm ... More >> Childhood Lymphoma Childhood Solid Neoplasm Pineal Region Neoplasm Recurrent Childhood Central Nervous System Neoplasm Recurrent Childhood Visual Pathway Glioma Refractory Central Nervous System Neoplasm Less << | Phase 1 | Recruiting | - | - |
NCT02936752 | Blasts 21-30 Percent of Bone M... More >>arrow Nucleated Cells Myelodysplastic Syndrome Previously Treated Myelodysplastic Syndrome Less << | Phase 1 | Recruiting | June 30, 2019 | United States, Connecticut ... More >> Smilow Cancer Center/Yale-New Haven Hospital Recruiting New Haven, Connecticut, United States, 06510 Contact: Site Public Contact 203-785-5702 canceranswers@yale.edu Principal Investigator: Amer M. Zeidan Yale University Recruiting New Haven, Connecticut, United States, 06520 Contact: Site Public Contact 203-785-5702 canceranswers@yale.edu Principal Investigator: Amer M. Zeidan United States, Kentucky University of Kentucky/Markey Cancer Center Recruiting Lexington, Kentucky, United States, 40536 Contact: Site Public Contact 859-257-3379 Principal Investigator: Reshma Ramlal United States, North Carolina Duke University Medical Center Recruiting Durham, North Carolina, United States, 27710 Contact: Site Public Contact 888-275-3853 Principal Investigator: James L. Abbruzzese Less << |
NCT02820961 | Breast Cancer ... More >> Estrogen Receptor Positive Breast Cancer Less << | Phase 1 | Active, not recruiting | December 2018 | United States, Colorado ... More >> Sarah Cannon Research Institute HealthONE Denver, Colorado, United States, 80218 United States, Florida Florida Cancer Specialists Sarasota, Florida, United States, 34232 United States, Tennessee Sarah Cannon Research Institute Nashville, Tennessee, United States, 37203 Less << |
NCT03765229 | Melanoma | Phase 2 | Not yet recruiting | June 2023 | - |
NCT03179930 | Lymphoma Rela... More >>psed Refractory Less << | Phase 2 | Recruiting | June 2019 | United States, New Jersey ... More >> Memorial Sloan Kettering Basking Ridge Recruiting Basking Ridge, New Jersey, United States, 07920 Contact: Anas Younes, MD 212-639-7715 Memorial Sloan Kettering Monmouth Recruiting Middletown, New Jersey, United States, 07748 Contact: Anas Younes, MD 212-639-7715 Memorial Sloan Kettering Bergen Recruiting Montvale, New Jersey, United States, 07645 Contact: Anas Younes, MD 212-639-7715 United States, New York Memorial Sloan Kettering Commack Recruiting Commack, New York, United States, 11725 Contact: Anas Younes, MD 212-639-7715 Memorial Sloan Kettering Westchester Recruiting Harrison, New York, United States, 10604 Contact: Anas Younes, MD 212-639-7715 Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Anas Younes, MD 212-639-7715 Contact: Allison Moskowitz, MD 212-639-4839 Principal Investigator: Anas Younes, MD Memorial Sloan Kettering Rockville Centre Recruiting Rockville Centre, New York, United States, 11570 Contact: Anas Younes, MD 212-639-7715 Less << |
NCT02922933 | Volunteers He... More >>althy Volunteers Human Volunteers Normal Volunteers Less << | Phase 1 | Completed | - | United States, Arizona ... More >> Celerion Tempe, Arizona, United States, 85283 United States, Nebraska Celerion Lincoln, Nebraska, United States, 68502 Less << |
NCT02708680 | Breast Cancer | Phase 1 Phase 2 | Active, not recruiting | January 2020 | - |
NCT03211988 | Neuroendocrine Tumors | PHASE2 | TERMINATED | 2021-12-31 | Columbia University Irving Med... More >>ical Center, New York, New York, 10032, United States Less << |
NCT03552380 | Renal Cell Carcinoma | Phase 2 | Recruiting | August 2020 | United States, Indiana ... More >> Indiana Univeristy Melvin and Bren Simon Cancer Center Recruiting Indianapolis, Indiana, United States, 46202 Contact: Roberto Pili, MD 317-278-7776 rpili@iu.edu Principal Investigator: Roberto Pili, MD Less << |
NCT03473639 | Metastatic Breast Cancer ... More >> Breast Cancer Less << | Phase 1 | Recruiting | October 15, 2028 | United States, Virginia ... More >> University of Virginia Recruiting Charlottesville, Virginia, United States, 22908 Contact: Sue Jones, BSN, RN, OCN, CCRP 44 924 9199 syt8a@virginia.edu Principal Investigator: Patrick Dillon, MD Less << |
NCT03361800 | Breast Cancer|Invasive Breast ... More >>Cancer|ER-Negative PR-Negative HER2-Negative Breast Cancer Less << | EARLY_PHASE1 | TERMINATED | 2019-10-11 | Lineberger Comprehensive Cance... More >>r Center at University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, 27599, United States Less << |
NCT02833155 | Breast Cancer | Phase 1 | Recruiting | September 2018 | China, Beijing ... More >> Cancer Hospital Chinese Academy Medical Sciences Recruiting Beijing, Beijing, China, 100021 Contact: Jingjing Wang +8615010581751 China, Hunan Hunan Cancer Hospital Not yet recruiting Changsha, Hunan, China, 410013 China, Sichuan West China Hospital Not yet recruiting Chengdu, Sichuan, China, 610041 Contact: Hong Zheng, MD China, Tianjin Tianjin Medical University Cancer Institute & Hospital Not yet recruiting Tianjin, Tianjin, China, 300000 Less << |
NCT03760614 | Pancreas Cancer | Phase 1 | Not yet recruiting | November 2020 | - |
NCT03187015 | Drug Interaction ... More >> Healthy Volunteer Less << | Phase 1 | Completed | - | United States, Nebraska ... More >> Celerion Lincoln, Nebraska, United States, 68502 Less << |
NCT03192111 | Renal Impairment|Healthy Volun... More >>teer Less << | PHASE1 | COMPLETED | 2017-11-23 | Clinical Pharmacology of Miami... More >>, Miami, Florida, 33014, United States|Orlando Clinical Research Center, Orlando, Florida, 32809, United States|New Orleans Center for Clinical Research, Knoxville, Tennessee, 37920, United States Less << |
NCT02915523 | Epithelial Ovarian Cancer ... More >> Peritoneal Cancer Fallopian Tube Cancer Less << | Phase 1 Phase 2 | Active, not recruiting | March 2021 | United States, Florida ... More >> H. Lee Moffitt Cancer Center and Research Tampa, Florida, United States, 33612 Florida Cancer Specialist East Region (SCRI Affiliate) West Palm Beach, Florida, United States, 33401 United States, Illinois University of Chicago Chicago, Illinois, United States, 60637 United States, Maryland Greater Baltimore Medical Center Baltimore, Maryland, United States, 21204 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University Baltimore, Maryland, United States, 21287 United States, Massachusetts Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Dana Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, Missouri HCA Midwest Health (SCRI Affiliate) Kansas City, Missouri, United States, 64131 United States, New York Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 United States, Pennsylvania University of Pennsylvania Philadelphia, Pennsylvania, United States, 19107 United States, Tennessee Sarah Cannon Research Institute Nashville, Tennessee, United States, 37204 United States, Virginia University of Virginia Charlottesville, Virginia, United States, 22908 Less << |
NCT02922946 | Volunteers|Healthy Volunteers|... More >>Human Volunteers|Normal Volunteers Less << | PHASE1 | COMPLETED | 2017-06-26 | Celerion, Lincoln, Nebraska, 6... More >>8502, United States Less << |
NCT02897778 | Neoplasms Neo... More >>plasms, Glandular and Epithelial Neoplasms by Histologic Type Bronchial Neoplasms Lung Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms Digestive System Neoplasms Endocrine Gland Neoplasms Carcinoma, Non-Small-Cell Lung Lung Diseases Breast Neoplasms Breast Diseases Renal Neoplasm Solid Tumors Less << | Phase 1 | Completed | - | United States, Texas ... More >> The START Center for Cancer Care San Antonio, Texas, United States, 78229 Less << |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
2.66mL 0.53mL 0.27mL |
13.28mL 2.66mL 1.33mL |
26.57mL 5.31mL 2.66mL |